TCM
CMPX icon

Tang Capital Management’s Compass Therapeutics CMPX Stock Holding History

Tang Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.8M Hold
16,790,809
– – 4.51% 11
2025
Q4 		$90.2M Sell
16,790,809
-21,154
-0.1% -$97.7K 4.45% 9
2025
Q3 		$58.8M Buy
16,811,963
+3,315,755
+25% +$10.5M 2.27% 10
2025
Q2 		$35.1M Buy
13,496,208
+2,443,576
+22% +$5.04M 1.77% 13
2025
Q1 		$21M Buy
11,052,632
+5,152,632
+87% +$13.7M 1.16% 23
2024
Q4 		$8.55M Buy
5,900,000
+4,087,005
+225% +$6.79M 0.57% 49
2024
Q3 		$3.34M Buy
+1,812,995
New +$2.26M 0.24% 87

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Tang Capital Management's CMPX Position: Q1 2026 in Review

Tang Capital Management held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 16,790,809 shares worth $88.8M. The position accounts for 4.51% of the portfolio, ranked #11.

Tang Capital Management first reported a position in CMPX in Q3 2024 and has held it in 7 quarters since. The position peaked at $90.2M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Tang Capital Management held 16,790,809 shares of Compass Therapeutics worth $88.8M as of Q1 2026.
  • Tang Capital Management left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up 4.51% of Tang Capital Management's portfolio in Q1 2026, its #11 holding.
  • Tang Capital Management first reported a position in Compass Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Tang Capital Management's Compass Therapeutics position peaked at $90.2M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.